Itama Ranoraya
PT Itama Ranoraya Tbk is a high-tech healthcare solutions provider based in Indonesia, committed to delivering exceptional customer experiences through innovative medical equipment and services. Since 2000, the company has established partnerships with leading healthcare principles both locally and internationally, and operates a widespread distribution network across Indonesia. The company is actively transforming its business to include manufacturing, clinical laboratory, and e-health services, aiming for sustainable growth and increased contribution to the healthcare sector.
Industries
Nr. of Employees
medium (51-250)
Products
Single‑use syringes (ADS)
Auto‑disable single‑use syringes manufactured for mass immunization and routine use.
Safety needles
Safety‑engineered needle products produced for clinical safety and sharps injury prevention.
Point‑of‑care antigen diagnostic tests
Rapid in‑vitro diagnostic tests for point‑of‑care detection used in mass screening and retail channels.
Apheresis/plasma collection systems
Supply and support for apheresis systems used in plasma collection and therapeutic procedures.
Ultrasound imaging systems
Distribution and support for ultrasound (USG) diagnostic equipment for clinical imaging.
Alinity i
A compact, scalable clinical and blood screening system designed to maximize throughput and efficiency with a capacity of up to 200 tests per hour.
Single‑use syringes (ADS)
Auto‑disable single‑use syringes manufactured for mass immunization and routine use.
Safety needles
Safety‑engineered needle products produced for clinical safety and sharps injury prevention.
Point‑of‑care antigen diagnostic tests
Rapid in‑vitro diagnostic tests for point‑of‑care detection used in mass screening and retail channels.
Apheresis/plasma collection systems
Supply and support for apheresis systems used in plasma collection and therapeutic procedures.
Ultrasound imaging systems
Distribution and support for ultrasound (USG) diagnostic equipment for clinical imaging.
Alinity i
A compact, scalable clinical and blood screening system designed to maximize throughput and efficiency with a capacity of up to 200 tests per hour.
Services
National distribution of medical devices and diagnostics through a network of sub-distributors to government, institutional and retail customers.
Provision and operation of clinical laboratory testing services including COVID‑19 testing through partnerships and planned branch expansion.
Integration of diagnostic supply and laboratory services with telemedicine platforms and digital health services, leveraging data analytics.
Manufacture of single‑use syringes and safety needles and planned localization of diagnostic test production at in‑country facilities.
National distribution of medical devices and diagnostics through a network of sub-distributors to government, institutional and retail customers.
Provision and operation of clinical laboratory testing services including COVID‑19 testing through partnerships and planned branch expansion.
Integration of diagnostic supply and laboratory services with telemedicine platforms and digital health services, leveraging data analytics.
Manufacture of single‑use syringes and safety needles and planned localization of diagnostic test production at in‑country facilities.
Expertise Areas
- Medical device distribution
- Medical consumables manufacturing
- Clinical laboratory services
- Digital health and telemedicine integration
Key Technologies
- Point‑of‑care antigen testing
- In‑vitro diagnostics (IVD)
- Apheresis/plasma collection systems
- Ultrasound imaging systems
News & Updates
The company reported a significant growth in revenue and net profit for 2024, with revenue reaching approximately Rp 977 billion, up 40.38% from the previous year, and net profit increasing by 924.6%.
PT Itama Ranoraya Tbk supports access to chronic kidney disease treatment by distributing hemodialysis machines across Indonesia.
The company aims to achieve more than 80% growth in revenue in 2021, driven by high demand for its healthcare products, especially related to COVID-19 testing and treatment.
In 2020, PT Itama Ranoraya Tbk reported a net profit increase of 82.3%, reaching Rp 60.52 billion, driven by a 100.1% increase in revenue to Rp 563.89 billion, with significant contributions from in-vitro health products and COVID-19 related equipment.
PT Itama Ranoraya Tbk successfully conducted an IPO on October 15, 2019, raising Rp 149.6 billion by issuing 400 million shares at Rp 374 per share, with a strong investor response and share price increase of 49.73% on the first trading day.
The company reported a significant growth in revenue and net profit for 2024, with revenue reaching approximately Rp 977 billion, up 40.38% from the previous year, and net profit increasing by 924.6%.
PT Itama Ranoraya Tbk supports access to chronic kidney disease treatment by distributing hemodialysis machines across Indonesia.
The company aims to achieve more than 80% growth in revenue in 2021, driven by high demand for its healthcare products, especially related to COVID-19 testing and treatment.
In 2020, PT Itama Ranoraya Tbk reported a net profit increase of 82.3%, reaching Rp 60.52 billion, driven by a 100.1% increase in revenue to Rp 563.89 billion, with significant contributions from in-vitro health products and COVID-19 related equipment.
PT Itama Ranoraya Tbk successfully conducted an IPO on October 15, 2019, raising Rp 149.6 billion by issuing 400 million shares at Rp 374 per share, with a strong investor response and share price increase of 49.73% on the first trading day.